



# PROGRAM SYLLABUS



A Live Visiting Professor  
Grand Rounds Program  
*presented by*



Sponsored by:  
**POTOMAC CENTER for  
MEDICAL EDUCATION**



This program is supported  
through an educational grant from  
**Daiichi Sankyo, Inc. and Lilly USA, LLC**



## **Table of Contents**

---

Program Content and Format.....	Page 3
Target Audience/Learning Objectives .....	Page 4
CME Statements .....	Page 4
Disclosures .....	Page 5
Steering Committee Bios.....	Pages 6 – 7
Speaking Faculty Bios.....	Page 8

## Program Content and Format

---

Potomac Center for Medical Education welcomes you to “**Optimizing Protection for NSTEMI-ACS Patients with Antiplatelet Therapy**” a CME visiting professor presentation designed to give medical professionals the latest news and information on antiplatelet therapy.

Despite advances in acute and chronic treatment of acute coronary syndrome (ACS) patients, there is still considerable uncertainty among physicians about the relative benefits of various antiplatelet agents in protecting against long-term ischemic complications. Interventional cardiologists, general cardiologists, hospitalists, and the entire cath-lab staff have expressed a need for additional education on these issues. Education will clarify the subtle differences between available and emerging agents for preventing thrombotic events, including their relative risks for bleeding complications. As a result, the gap between physician knowledge of antiplatelet agents and the application of that knowledge in practice can be reduced, and the long-term management of ACS patients improved.

This program will also explore the limitations of current antiplatelet therapies and how they might be best managed. In addition, participants will be alerted to the potential importance of emerging therapies that can transform the clinical management of these patients.

**An online version of this CME program will also be available.** Go to [www.potomacme.org/nste-acs](http://www.potomacme.org/nste-acs) for more information.

## Target Audience

---

This program is intended for interventional cardiologists, ER physicians, and allied health professionals who treat patients with ACS.

## Educational Objectives

---

This activity was designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice

At the conclusion of this activity, participants should be able to:

- Explain the importance of long-term dual platelet inhibition to protect post-ACS and post-PCI patients against thromboembolic events
- Describe the strengths and limitations of current antiplatelet treatment options, along with the need to balance reduction of ischemic thromboembolic complications with minimization of excessive bleeding risks
- Discuss emerging oral antiplatelet treatments suitable for long-term protection against risks of thromboembolic events
- Differentiate patients and therapies to optimize therapeutic management of post-ACS and post-PCI


## Accreditation

---

The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## CME Credit

---

 The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 *AMA PRA Category I credit(s)*<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

## Special Services

---



Event staff will be glad to assist you with any special needs (e.g. physical, dietary, etc.).

## Receiving CME Credit

---

**To receive CME credit the participant must:**

- Sign in / sign out on the sheet provided by the host coordinator;
- Participate in the lecture;
- Complete & sign the registration and evaluation form;
- Return the registration and evaluation form to the host coordinator or mail to the address provided at the bottom of the document

## Disclosure Statement

---

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests::

**Sandeep Nathan, MD: *Speaker:*** Sanofi-Aventis, Medtronic Inc., Schering-Plough, Medtronic;  
***Consultant/Advisory Panel:*** Sanofi-Aventis, Medtronic Inc., Schering-Plough; ***Research Support:*** Medtronic Inc.

**Deepak L. Bhatt, MD, FACC, FAHA: *Investigator:*** Bristol-Myers Squibb, Eisai, Ethicon, HeartScape, Sanofi Aventis, The Medicines Company

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

**Barry Watkins, PhD; Robert Lamb, PharmD; Brad Pine; Blair St. Amand; Jay Katz; Dana Simpler, MD:** Nothing to Disclose

## FDA Disclosure

---

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

## Steering Committee

---



**SANDEEP NATHAN, MD**

Director of Cardiovascular Intervention  
Assistant Professor of Medicine  
Rush Medical College  
Chicago, IL

**Sandeep Nathan, MD** is an Assistant Professor of Medicine at the University of Chicago Pritzker School of Medicine and is on the Interventional Cardiology staff at the University of Chicago Medical Center.

Dr. Nathan earned his undergraduate and medical degrees from Boston University and completed his Internal Medicine residency training at the University of Pittsburgh Medical Center. He completed his fellowship in Cardiovascular Medicine at Rush University Medical Center, where he also served as Chief Cardiology Fellow and subsequently received training in cardiovascular and peripheral vascular intervention. He is a Fellow of the American College of Cardiology, as well as the Society of Cardiovascular Angiography and Interventions. He currently serves as an investigator for a number of industry and NIH-sponsored studies and registries. He has co-authored numerous abstracts, original scientific manuscripts, and textbook chapters in the areas of acute coronary syndromes, platelet inhibition, percutaneous coronary intervention, and cardiogenic shock.

## Steering Committee Cont'd

---



**DEEPAK L. BHATT, MD, FACC, FAHA**

Director, Integrated Interventional Cardiovascular Program  
Brigham and Women's Hospital  
Boston, MA

**Deepak L. Bhatt, MD, FACC, FAHA** is Chief of Cardiology of the VA Boston Healthcare System and Director of the Integrated Interventional Cardiovascular Program at Brigham and Women's Hospital and the VA Boston Healthcare System. He is also a Senior Investigator in the TIMI Study Group and is on the faculty of Harvard Medical School.

After graduating as valedictorian from the Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology, while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University. His internship and residency in internal medicine were performed at the Hospital of the University of Pennsylvania, and his cardiovascular training was completed at the Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention, as well as serving as chief interventional fellow at the Cleveland Clinic, where he went on to spend several years as an interventional cardiologist and an Associate Professor of Medicine. He served for many years as the Director of the Interventional Cardiology Fellowship and as Associate Director of the Cardiovascular Medicine Fellowship. He also served as the Associate Director of the Cleveland Clinic Cardiovascular Coordinating Center. Dr. Bhatt has been listed in Best Doctors in America every year since 2005.

Dr. Bhatt's research interests include preventive cardiology, as well as the optimal management of patients with acute coronary syndromes. He also has research interests in advanced techniques in cardiac, cerebral, and peripheral intervention. He has authored or co-authored more than 250 articles, he is on several editorial boards, and he is the editor of *Essential Concepts in Cardiovascular Intervention and Guide to Peripheral and Cerebrovascular Intervention*, as well as co-editor of the *Handbook of Acute Coronary Syndromes*. He is the international principal investigator for the CHARISMA and CRESCENDO trials and co-principal investigator of the CHAMPION and LANCELOT trials. He serves as the co-chair of the REACH registry, and he is also on the steering committees of several trials. Dr. Bhatt has been a visiting lecturer at a number of institutions throughout the world. He has been interviewed extensively by news agencies on topics ranging from premature coronary artery disease to the role of inflammation and genetics in heart attacks.

## Faculty Speaker

---